Zum Hauptinhalt springen

Press Releases and Ad-hoc Announcements

04. September 2025
PR: Heidelberg Pharma Announces New Clinical Data on Lead ATAC Candidate HDP-101 to be Presented at International Myeloma Society Annual Meeting 2025
PDF
28. August 2025
AH: Heidelberg Pharma’s Partner Telix Pharmaceuticals Gives Regulatory Update for its Imaging Agent TLX250-CDx
PDF
10. Juli 2025
PR: Heidelberg Pharma Reports on First Half-Year 2025 and the Positive Course of Business
PDF
15. Mai 2025
PR: Heidelberg Pharma Reports on the Results of the Ordinary Annual General Meeting 2025 and New Supervisory Board
PDF
14. Mai 2025
PR: Heidelberg Pharma to Present Promising New Clinical Data on its Lead ATAC Candidate HDP-101 at EHA 2025
PDF
24. April 2025
PR: Heidelberg Pharma AG: Interim Statement on the First Three Months of Financial Year 2025
PDF
21. März 2025
PR: Heidelberg Pharma announces financial figures and reports on successful business performance in 2024
PDF
13. März 2025
PR: Heidelberg Pharma Amends Royalty Financing with HealthCare Royalty
PDF
13. März 2025
AH: Heidelberg Pharma Amends Royalty Financing with HealthCare Royalty
PDF
13. Januar 2025
PR: Heidelberg Pharma Progresses into Cohort 7 in a Phase I/IIa Study with BCMA ATAC Candidate HDP-101 Targeting Multiple Myeloma
PDF